Double trouble for CML.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 28381535.
- Also identified by DOI 10.1126/scitranslmed.aan2773.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Combining two BCR-ABL1 inhibitors with nonoverlapping mechanisms of action eradicates CML and prevents recurrence.
Medical subject headings
- Fusion Proteins, bcr-abl
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive